- Report
- July 2024
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- January 2025
- 146 Pages
Global
From €2639EUR$2,900USD£2,263GBP
- Report
- October 2024
- 199 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- September 2021
- 40 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- October 2023
- 129 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- March 2024
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2023
- 133 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2023
- 90 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2024
- 112 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- November 2023
- 95 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Coagulants are a type of hematological drug used to treat and prevent excessive bleeding. They work by helping the body form clots to stop bleeding. Coagulants are used to treat a variety of conditions, including hemophilia, deep vein thrombosis, and pulmonary embolism. They are also used to prevent excessive bleeding during surgery and childbirth. Coagulants are available in both oral and injectable forms.
The coagulant market is a rapidly growing segment of the hematological drug market. It is driven by the increasing prevalence of bleeding disorders, the growing demand for safer and more effective treatments, and the development of new drugs. The market is expected to continue to grow in the coming years, driven by the increasing demand for coagulants and the development of new drugs.
Some of the major companies in the coagulant market include Bayer AG, Pfizer Inc., Novo Nordisk A/S, Sanofi S.A., and CSL Behring. Show Less Read more